Simultaneous Detection of Tumor Derived Exosomal Protein–MicroRNA Pairs with an Exo-PROS Biosensor for Cancer Diagnosis

Chang-Chieh Hsu; Yunchen Yang; Eric Kannisto; Xie Zeng; Guan Yu; Santosh K. Patnaik; Grace K. Dy; Mary E. Reid; Qiaoqiang Gan; Yun Wu

doi:10.1021/acsnano.2c10970

Simultaneous Detection of Tumor Derived Exosomal Protein–MicroRNA Pairs with an Exo-PROS Biosensor for Cancer Diagnosis

Chang-Chieh Hsu, Yunchen Yang, Eric Kannisto, Xie Zeng, Guan Yu, Santosh K. Patnaik, Grace K. Dy, Mary E. Reid, Qiaoqiang Gan, Yun Wu

Research output: Contribution to journal › Article › peer-review

27 Scopus citations

Abstract

Tumor derived exosomes (TEXs) have emerged as promising biomarkers for cancer liquid biopsy. Conventional methods (such as ELISA and qRT-PCR) and emerging biosensing technologies mainly detect a single type of exosomal biomarker due to the distinct properties of different biomolecules. Sensitive detection of two different types of TEX biomarkers, i.e., protein and microRNA combined biomarkers, may greatly improve cancer diagnostic accuracy. We developed an exosome protein microRNA one-stop (Exo-PROS) biosensor that not only selectively captured TEXs but also enabled in situ, simultaneous detection of TEX protein–microRNA pairs via a surface plasmon resonance mechanism. Exo-PROS assay is a fast, reliable, low sample consumption, and user-friendly test. With a total of 175 cancer patients and normal controls, we demonstrated that TEX protein–microRNA pairs measured by Exo-PROS assay detected lung cancer and breast cancer with 99% and 96% accuracy, respectively. Exo-PROS assay also showed superior diagnostic performance to conventional ELISA and qRT-PCR methods. Our results demonstrated that Exo-PROS assay is a potent liquid biopsy assay for cancer diagnosis.

Original language	English (US)
Journal	ACS Nano
DOIs	https://doi.org/10.1021/acsnano.2c10970
State	Published - Apr 27 2023

ASJC Scopus subject areas

General Physics and Astronomy
General Materials Science
General Engineering

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1021/acsnano.2c10970

Cite this

@article{a1f183372b814b7b8e42551806c50c62,

title = "Simultaneous Detection of Tumor Derived Exosomal Protein–MicroRNA Pairs with an Exo-PROS Biosensor for Cancer Diagnosis",

abstract = "Tumor derived exosomes (TEXs) have emerged as promising biomarkers for cancer liquid biopsy. Conventional methods (such as ELISA and qRT-PCR) and emerging biosensing technologies mainly detect a single type of exosomal biomarker due to the distinct properties of different biomolecules. Sensitive detection of two different types of TEX biomarkers, i.e., protein and microRNA combined biomarkers, may greatly improve cancer diagnostic accuracy. We developed an exosome protein microRNA one-stop (Exo-PROS) biosensor that not only selectively captured TEXs but also enabled in situ, simultaneous detection of TEX protein–microRNA pairs via a surface plasmon resonance mechanism. Exo-PROS assay is a fast, reliable, low sample consumption, and user-friendly test. With a total of 175 cancer patients and normal controls, we demonstrated that TEX protein–microRNA pairs measured by Exo-PROS assay detected lung cancer and breast cancer with 99% and 96% accuracy, respectively. Exo-PROS assay also showed superior diagnostic performance to conventional ELISA and qRT-PCR methods. Our results demonstrated that Exo-PROS assay is a potent liquid biopsy assay for cancer diagnosis.",

author = "Chang-Chieh Hsu and Yunchen Yang and Eric Kannisto and Xie Zeng and Guan Yu and Patnaik, {Santosh K.} and Dy, {Grace K.} and Reid, {Mary E.} and Qiaoqiang Gan and Yun Wu",

note = "KAUST Repository Item: Exported on 2023-05-02 Acknowledgements: The authors acknowledge funding support from National Cancer Institute (NCI) of the National Institutes of Health (NIH) under award numbers R21CA235305 (YW and QG), R33CA191245 (YW), and R01CA272827 (YW). Deidentified human serum samples and clinical data were provided by the Data Bank and BioRepository (DBBR), which is funded by NCI under award number P30CA16056 and is a Roswell Park Cancer Institute Cancer Center Support Grant shared resource. The authors thank the support from National Science Foundation under award number CBET-1337860, which funds the nanoparticle tracking analysis system (NanoSight, LM10, Malvern Instruments Ltd.). The content is solely the responsibility of the authors and does not necessarily represent the official views of NIH and NSF. The authors thank Dr. Min Gao and the TEM facility at the Advanced Materials and Liquid Crystal Institute at Kent State University for the cryo-TEM characterization of exosomes.",

year = "2023",

month = apr,

day = "27",

doi = "10.1021/acsnano.2c10970",

language = "English (US)",

journal = "ACS Nano",

issn = "1936-0851",

publisher = "American Chemical Society",

}

TY - JOUR

T1 - Simultaneous Detection of Tumor Derived Exosomal Protein–MicroRNA Pairs with an Exo-PROS Biosensor for Cancer Diagnosis

AU - Hsu, Chang-Chieh

AU - Yang, Yunchen

AU - Kannisto, Eric

AU - Zeng, Xie

AU - Yu, Guan

AU - Patnaik, Santosh K.

AU - Dy, Grace K.

AU - Reid, Mary E.

AU - Gan, Qiaoqiang

AU - Wu, Yun

N1 - KAUST Repository Item: Exported on 2023-05-02 Acknowledgements: The authors acknowledge funding support from National Cancer Institute (NCI) of the National Institutes of Health (NIH) under award numbers R21CA235305 (YW and QG), R33CA191245 (YW), and R01CA272827 (YW). Deidentified human serum samples and clinical data were provided by the Data Bank and BioRepository (DBBR), which is funded by NCI under award number P30CA16056 and is a Roswell Park Cancer Institute Cancer Center Support Grant shared resource. The authors thank the support from National Science Foundation under award number CBET-1337860, which funds the nanoparticle tracking analysis system (NanoSight, LM10, Malvern Instruments Ltd.). The content is solely the responsibility of the authors and does not necessarily represent the official views of NIH and NSF. The authors thank Dr. Min Gao and the TEM facility at the Advanced Materials and Liquid Crystal Institute at Kent State University for the cryo-TEM characterization of exosomes.

PY - 2023/4/27

Y1 - 2023/4/27

N2 - Tumor derived exosomes (TEXs) have emerged as promising biomarkers for cancer liquid biopsy. Conventional methods (such as ELISA and qRT-PCR) and emerging biosensing technologies mainly detect a single type of exosomal biomarker due to the distinct properties of different biomolecules. Sensitive detection of two different types of TEX biomarkers, i.e., protein and microRNA combined biomarkers, may greatly improve cancer diagnostic accuracy. We developed an exosome protein microRNA one-stop (Exo-PROS) biosensor that not only selectively captured TEXs but also enabled in situ, simultaneous detection of TEX protein–microRNA pairs via a surface plasmon resonance mechanism. Exo-PROS assay is a fast, reliable, low sample consumption, and user-friendly test. With a total of 175 cancer patients and normal controls, we demonstrated that TEX protein–microRNA pairs measured by Exo-PROS assay detected lung cancer and breast cancer with 99% and 96% accuracy, respectively. Exo-PROS assay also showed superior diagnostic performance to conventional ELISA and qRT-PCR methods. Our results demonstrated that Exo-PROS assay is a potent liquid biopsy assay for cancer diagnosis.

AB - Tumor derived exosomes (TEXs) have emerged as promising biomarkers for cancer liquid biopsy. Conventional methods (such as ELISA and qRT-PCR) and emerging biosensing technologies mainly detect a single type of exosomal biomarker due to the distinct properties of different biomolecules. Sensitive detection of two different types of TEX biomarkers, i.e., protein and microRNA combined biomarkers, may greatly improve cancer diagnostic accuracy. We developed an exosome protein microRNA one-stop (Exo-PROS) biosensor that not only selectively captured TEXs but also enabled in situ, simultaneous detection of TEX protein–microRNA pairs via a surface plasmon resonance mechanism. Exo-PROS assay is a fast, reliable, low sample consumption, and user-friendly test. With a total of 175 cancer patients and normal controls, we demonstrated that TEX protein–microRNA pairs measured by Exo-PROS assay detected lung cancer and breast cancer with 99% and 96% accuracy, respectively. Exo-PROS assay also showed superior diagnostic performance to conventional ELISA and qRT-PCR methods. Our results demonstrated that Exo-PROS assay is a potent liquid biopsy assay for cancer diagnosis.

UR - http://hdl.handle.net/10754/691364

UR - https://pubs.acs.org/doi/10.1021/acsnano.2c10970

U2 - 10.1021/acsnano.2c10970

DO - 10.1021/acsnano.2c10970

M3 - Article

C2 - 37129374

SN - 1936-0851

JO - ACS Nano

JF - ACS Nano

ER -

Simultaneous Detection of Tumor Derived Exosomal Protein–MicroRNA Pairs with an Exo-PROS Biosensor for Cancer Diagnosis

Abstract

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this